These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 20303155)

  • 1. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
    Lodde M; Lacombe L; Fradet Y
    Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
    Lau YK; Chadha MK; Litwin A; Trump DL
    J Hematol Oncol; 2008 Nov; 1():21. PubMed ID: 18986533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
    Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
    Iversen P; Roder MA
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of bicalutamide in adjuvant treatment of prostatic carcinoma after primary therapy with curative aim. The viewpoint of the surgeon].
    Rigatti P; Scattoni V
    Recenti Prog Med; 2002 Mar; 93(3):183-5. PubMed ID: 11942171
    [No Abstract]   [Full Text] [Related]  

  • 10. Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience.
    Okegawa T; Nutahara K; Higashihara E
    Int J Urol; 2010 Nov; 17(11):950-5. PubMed ID: 20807265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer : a single center experience].
    Takada T; Ishizuya Y; Okada T; Ueda T; Inoue H; Hara T
    Hinyokika Kiyo; 2011 Jun; 57(6):291-5. PubMed ID: 21795830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
    Sciarra A; Di Silverio F
    Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adjuvant treatment of prostatic carcinoma after primary therapy. The "Early Prostate Cancer" Program].
    Mansueto G; Longo F
    Recenti Prog Med; 2002 Mar; 93(3):175-8. PubMed ID: 11942169
    [No Abstract]   [Full Text] [Related]  

  • 15. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
    Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
    BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
    Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal therapy of prostate cancer.
    Labrie F
    Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis.
    McGivern U; Mitchell DM; McDowell C; O'Hare J; Corey G; O'Sullivan JM
    Clin Genitourin Cancer; 2012 Sep; 10(3):190-5. PubMed ID: 22677511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
    Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
    Spitz IM; Chertin B; Fridmans A; Farkas A; Belanger A; Hartman H; Labrie F
    Prostate Cancer Prostatic Dis; 2009; 12(1):100-3. PubMed ID: 18574491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.